Targeting transcription factors in cancer: Challenges and evolving strategies

Drug Discovery Today: Technologies

Volumn 3, Issue 3, 2006, Pages 261-267

  Redell, Michele S ^a   Tweardy, David J ^b  

^a TEXAS CHILDREN S CANCER CENTER   (United States)

^b Section of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIFUNGAL AGENT; ANTISENSE OLIGONUCLEOTIDE; AVI 4126; BETA CATENIN; CAND 5; DECOY OLIGONUCLEOTIDE; DENDRIMER; G QUARTET OLIGONUCLEOTIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LIPOSOME; MICROBICIDE; MYC PROTEIN; OLIGONUCLEOTIDE; ONCOMYC NG; SHORT HAIRPIN RNA; SIRNA 027; SMALL MOLECULE INHIBITOR; STAT3 PROTEIN; STAT5 PROTEIN; STEROID RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ADENO ASSOCIATED VIRUS; ADENOVIRUS VECTOR; ANGIOGENESIS; APOPTOSIS; CANCER; CANCER INVASION; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL PROLIFERATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; GENE EXPRESSION; GENE OVEREXPRESSION; HERPESVIRUS VECTOR; HIGH THROUGHPUT SCREENING; HUMAN; LENTIVIRUS VECTOR; METASTASIS; NANOPARTICLE; NONHUMAN; PROGNOSIS; RETROVIRUS VECTOR; REVIEW; RNA INTERFERENCE; UNSPECIFIED SIDE EFFECT;

EID: 33751003260     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2006.09.010     Document Type: Review

References (40)

1. Gronemeyer H., et al. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3 (2004) 950-964
2. Turkson J., and Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19 (2000) 6613-6626
3. Mora L.B., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62 (2002) 6659-6666
4. Bromberg J.F., et al. Stat3 as an oncogene. Cell 98 (1999) 295-303
5. Kortylewski M., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11 (2005) 1314-1321
6. Grandis J.R., et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. U S A 97 (2000) 4227-4232
7. Jing N., et al. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol. Cancer Ther. 5 (2006) 279-286
8. Xi S., et al. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res. 63 (2003) 6763-6771
9. Karin M. Nuclear factor-κB in cancer development and progression. Nature 441 (2006) 431-436
10. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. 3 (2003) 721-732
11. Luu H.H., et al. Wnt/β-catenin signaling pathway as novel cancer drug targets. Curr. Cancer Drug Targets 4 (2004) 653-671
12. Ponzielli R., et al. Cancer therapeutics: targeting the dark side of Myc. Eur. J. Cancer 41 (2005) 2485-2501
13. Iversen P.L., et al. Efficacy of antisense morpholino oligomer target to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin. Cancer Res. 9 (2003) 2510-2519
14. Blaskovich M.A., et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63 (2003) 1270-1279
15. Jing N., et al. G-quartet oligonucleotides: a new class of Stat3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res. 64 (2004) 6603-6609
16. Stein C.A., et al. Antisense strategies for oncogene inactivation. Semin. Oncol. 32 (2005) 563-572
17. Arora V., et al. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr. Pharm. Biotechnol. 5 (2004) 431-439
18. Dykxhoorn D.M., et al. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 13 (2006) 541-552
19. Pan X., and Lee R.J. Tumour-selective drug delivery via folate receptor-targeted liposomes. Expert Opin. Drug Deliv. 1 (2004) 7-17
20. Kontermann R.E. Immunoliposomes for cancer therapy. Curr. Opin. Mol. Ther. 8 (2006) 39-45
21. Verma I.M., and Weitzman M.D. Gene therapy: twenty-first century medicine. Annu. Rev. Biochem. 74 (2005) 711-738
22. 2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
23. Dufes C., et al. Dendrimers in gene delivery. Adv. Drug Deliv. Rev. 57 (2005) 2177-2202
24. Schiffelers R.M., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32 (2004) e149
25. Chiarle R., et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11 (2005) 623-629
26. Xi S., et al. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24 (2005) 970-979
27. Barton B.E., et al. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol. Cancer Ther. 3 (2004) 1183-1191
28. Gao L., et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin. Cancer Res. 11 (2005) 6333-6341
29. Guo J., et al. Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-κB p65 subunit. Clin. Cancer Res. 10 (2004) 3333-3341
30. Huang Y.-T., et al. YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells. Mol. Cancer Ther. 4 (2005) 1628-1635
31. Matsumoto G., et al. Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin. Cancer Res. 11 (2005) 1287-1293
32. Olsen L.S., et al. Anticancer agent CHS 828 suppresses nuclear factor-κB activity in cancer cells through downregulation of IKK activity. Int. J. Cancer 111 (2004) 198-205
33. Yeo E.-J., et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95 (2003) 516-525
34. Sun X., et al. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8 (2001) 638-645
35. Roh H., et al. Suppression of β-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res. 61 (2001) 6563-6568
36. Verma U.N., et al. Small interfering RNAs directed against β-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9 (2003) 1291-1300
37. Emami K.H., et al. A small molecule inhibitor of β-catenin/CREB-binding protein transcription. Proc. Natl. Acad. Sci. U S A 101 (2004) 12682-12687
38. Leonetti C., et al. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther. 8 (2001) 459-468
39. Pastorino F., et al. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin. Cancer Res. 9 (2003) 4595-4605
40. Arkin M.R., and Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3 (2004) 301-317